These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36254197)

  • 21. Novel insights and therapeutic interventions for pediatric osteosarcoma.
    Kager L; Tamamyan G; Bielack S
    Future Oncol; 2017 Feb; 13(4):357-368. PubMed ID: 27651036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
    Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
    Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.
    Cascini C; Chiodoni C
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of apoptosis-related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients.
    Hong J; Li Q; Wang X; Li J; Ding W; Hu H; He L
    J Clin Lab Anal; 2022 Jul; 36(7):e24501. PubMed ID: 35576501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.
    Zhou Y; Li G; Li H; Lai F; Duan P; Cheng M
    J Immunol Res; 2022; 2022():1377565. PubMed ID: 35836470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.
    Dumars C; Ngyuen JM; Gaultier A; Lanel R; Corradini N; Gouin F; Heymann D; Heymann MF
    Oncotarget; 2016 Nov; 7(48):78343-78354. PubMed ID: 27823976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma.
    Wang Q; Zhang W; Guo Y; Li Y; Fu K
    Aging (Albany NY); 2021 Nov; 13(21):24155-24170. PubMed ID: 34747719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
    Ying H; Li ZQ; Li MP; Liu WC
    Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
    Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteosarcoma subtypes based on platelet-related genes and tumor microenvironment characteristics.
    Shu Y; Peng J; Feng Z; Hu K; Li T; Zhu P; Cheng T; Hao L
    Front Oncol; 2022; 12():941724. PubMed ID: 36212395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma.
    Lei T; Qian H; Lei P; Hu Y
    Cancer Sci; 2021 Nov; 112(11):4785-4798. PubMed ID: 34506683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastasis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma.
    Qin S; Li L; Liu D
    Aging (Albany NY); 2023 Jul; 15(14):7219-7236. PubMed ID: 37494671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immune landscape of solid pediatric tumors.
    Sherif S; Roelands J; Mifsud W; Ahmed EI; Raynaud CM; Rinchai D; Sathappan A; Maaz A; Saleh A; Ozer E; Fakhro KA; Mifsud B; Thorsson V; Bedognetti D; Hendrickx WRL
    J Exp Clin Cancer Res; 2022 Jun; 41(1):199. PubMed ID: 35690832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.
    Lamoureux F; Trichet V; Chipoy C; Blanchard F; Gouin F; Redini F
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):169-81. PubMed ID: 17288528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of exosomal miR‑21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review).
    Wang S; Ma F; Feng Y; Liu T; He S
    Int J Oncol; 2020 May; 56(5):1055-1063. PubMed ID: 32319566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Immune-Stromal Score-Based Gene Signature and Molecular Subtypes in Osteosarcoma: Implications for Prognosis and Tumor Immune Microenvironment.
    Zheng D; Yang K; Chen X; Li Y; Chen Y
    Front Genet; 2021; 12():699385. PubMed ID: 34630511
    [No Abstract]   [Full Text] [Related]  

  • 38. [The clinical predictors for the prognosis of patients with osteosarcoma].
    Yang QK; Chen T; Wang W; Liu F; Yao ZX; Zhang XJ
    Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):516-522. PubMed ID: 34034469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of immune-related genes as prognostic biomarkers for the assessment of osteosarcoma clinical outcomes.
    Guo J; Li X; Shen S; Wu X
    Sci Rep; 2021 Dec; 11(1):24123. PubMed ID: 34916564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma.
    Zhang C; Zheng JH; Lin ZH; Lv HY; Ye ZM; Chen YP; Zhang XY
    Aging (Albany NY); 2020 Feb; 12(4):3486-3501. PubMed ID: 32039832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.